Plexium is a technology-first drug development company. We aim to improve efficiencies across the entire drug-development spectrum by leveraging techniques from various physical-science and computational disciplines.

In the near term we aim to enlarge the class of biological targets amenable to small-molecule modulation by recruiting the cells protein degradation machinery to targets of interest. Rather than use bi-functional molecules that link target-binders to E3 ligases, we develop ‘molecular glues’ that modify E3 ligase substrate-recognition. Our engineering background allows us to empirically search for molecular-glue degraders in massively high throughput cell-based assays utilizing DNA-encoded libraries.

Our long-terms interests are in studying biology and chemistry simultaneously, in relation and in response to each other, at extremely high throughputs, using multiplexed, unbiased assay readouts. We believe these tools have inherent diagnostic value, providing insights into both biomarkers and disease mechanisms, which are crucial to minimizing clinical attrition. We dream of a future where therapies can be personalized rapidly and inexpensively by screening against functional equivalents of individuals. We believe the tools we are developing will make this future a reality.

Please come join us if you can help bridge the rigor of drug development with the creative urgency to transform medicine. We are a highly interdisciplinary team, and welcome the opportunity to talk with you!